Spruce Biosciences Announces Positive Results from 12-week, Phase 2a Study of Tildacerfont in Adults with Congenital Adrenal Hyperplasia
Advertisement
- Tildacerfont demonstrated maximum mean reductions of 84% adrenocorticotropic hormone (ACTH), 82% 17-hydroxyprogesterone (17-OHP) and 79% androstenedione (A4), key disease biomarkers in CAH patients with elevated androgens